Myself and a few fellow collaborators are in the early stages of creating a Protein Folding Program/Application designed to do just that "Fold Proteins for Diseases" but in this case all the Mosquito Related Illnesses.
The Program/Application will be usable on Home Computers, Tablets & even Smart phones as well as being able to Pool your Computing Power into the 1 "Folder" just like how CryptoCurrencies have Pooled mining.
In this case we are aiming for a better understanding with how these Diseases work & Mutate or the missing link for a "Cure"
The MOZZI cryptocurrency will be the Digital Backed Portion of the Project, linking the work that we do as a whole while laying the foundations for what we want to achieve
while proving its worth.
Interesting if it works. Can you give usmore details? How is it going to be different from FoldingCoin? How are you going to decentralize folding simulations? And why only mosquito diseases? Which proteins and which mutations do you have in mind to simulate?
Thanks
FoldingCoin runs off a variation of generic pre-built applications that are used and distributed Worldwide (Created by Harvard or other Groups) for Folding Proteins whereas MOZZI is taking a different approach with the mechanics of the system to hone in on specified Illnesses (Mosquito Born Viruses/Diseases)
Here is a run down on a Protein found to combat Dengue.Aedes aegypti is the primary vector of several medically relevant arboviruses including dengue virus (DENV) types 1–4.
Ae. aegypti transmits DENV by inoculating virus-infected saliva into host skin during probing and feeding.
Ae. aegypti saliva contains over one hundred unique proteins and these proteins have diverse functions, including facilitating blood feeding.
Previously, the Ae. aegypti salivary gland extracts (SGEs) enhanced dissemination of DENV to draining lymph nodes.
In contrast, HPLC-fractionation revealed that some SGE components inhibited infection.
D7 proteins are enriched in HPLC fractions that are inhibitory to DENV infection, and that recombinant D7 protein can inhibit DENV infection in vitro and in vivo.
Further, binding assays indicate that D7 protein can directly interact with DENV virions and recombinant DENV envelope protein.
Dengue virus (DENV) is transmitted to humans by Aedes aegypti during the blood feeding process.
During blood feeding, DENV and saliva proteins are inoculated into human skin.
D7 proteins are prevalent and immunogenic proteins present in Ae. aegypti saliva and assist the blood feeding process by scavenging biogenic amines.
Previous data suggests that antibodies against D7 protein from Culex spp. can increase West Nile virus infection.
The hypothesis is that D7 proteins may also have antiviral activity, studies suggest recombinant Ae. aegypti D7 protein can inhibit DENV infection in vitro and in vivo, and that D7 can bind to DENV virions.
This data reveals a novel role for D7 proteins, which inhibits arbovirus transmission to vertebrates through a direct interaction with virions.
To sum it up the D7 Protein is the main Target Protein to explore since it holds great hope with its Prior and Future findings.
